Optimal Interval Between Immune Therapy and Targeted Therapy with Sotorasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer
07:30am - 03:45pm EDT - March 31, 2023




Author(s):
Tags: Member Institution Clinical Oncology

Display Label Action
048-General Poster Session Download Handout